Merck & Co., Inc. (MRK)[Tv]

Key Developments

• Merck’s Q2 2026 earnings report on August 4, 2026, is the defining market event, expected to deliver a catastrophic $0.26 EPS loss—an 112% YoY decline—amid soaring revenue, signaling a fundamental breakdown in earnings sustainability despite strong top-line performance and pipeline momentum.

• The $5.7 billion one-time charge from the Terns Pharmaceuticals acquisition—driving a 160.3% effective tax rate and a 48% cut in full-year non-GAAP EPS guidance—has redefined investor expectations, exposing the high cost and capital inefficiency of Merck’s aggressive M&A strategy.

• The FDA approval of LIPFENDRA, Merck’s first oral PCSK9 inhibitor, marks a transformative entry into the high-growth cardiometabolic space, representing a credible diversification path beyond oncology and a strategic pivot amid intensifying patent cliff pressures.